Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;11(7):1605-1606.
doi: 10.1007/s13300-020-00844-8. Epub 2020 May 23.

Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends

Antonio Carlo Bossi  1 , Franco Forloni  2 , Paolo Luigi Colombelli  3
Affiliations

Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends

Antonio Carlo Bossi et al. Diabetes Ther. 2020 Jul.
No abstract available

Keywords: COVID-19 related pneumonia; Non-diabetic patients; SGLT2-inhibitors.

PubMed Disclaimer

References

    1. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122. doi: 10.2337/dc16-0542. - DOI - PubMed
    1. Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356–363. doi: 10.2337/dc17-1096. - DOI - PubMed
    1. Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–2117. doi: 10.1007/s00125-018-4670. - DOI - PubMed
    1. Baartscheer A, Schumacher CA, Wust RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60:568–573. doi: 10.1007/s00125-016-4134-x. - DOI - PMC - PubMed
    1. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44:457–464. doi: 10.1016/j.diabet.2018.09.005. - DOI - PubMed

LinkOut - more resources